Quality of Life in Cutaneous T-cell Lymphoma Patients Receiving Mogamulizumab: Important Factors to Consider.

Rosanne OttevangerSylvia van BeugenAndrea W M EversRein Willemze Maarten H VermeerKoen D Quint

Published in: Cancers (2022)

In general, mogamulizumab has a favorable effect on biochemical- and dermatology-specific QoL and physical functioning in some patients, with high treatment satisfaction. Itch especially improved over time in most patients. The treatment satisfaction was generally high. Mogamulizumab seems to be an effective treatment that improves the QoL in patients with E-CTCL.

Keyphrases

end stage renal disease
mental health
newly diagnosed
ejection fraction
physical activity
prognostic factors
replacement therapy